Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04623944 · ClinicalTrials.gov registry record · Phase 1
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
A Phase 1 study of MDS and AML, Adult, sponsored by Nkarta.
- Active
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 8
- Study locations
NCT04623944: Active Phase 1 study of MDS and AML, Adult, sponsored by Nkarta.
NCT04623944 is a Phase 1 study of MDS and AML, Adult that is active but no longer recruiting, run by Nkarta. The registered enrollment target is 61 participants, below the 94-participant average among 22 other MDS trials with a reported enrollment target (35% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04623944, a Phase 1 study of MDS and AML, Adult, is active but no longer recruiting, sponsored by Nkarta.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.
Primary Outcome
Incidence, nature, and severity of treatment related adverse events will be evaluated. An adverse event is any unfavorable and unintended sign including clinically significant abnormal laboratory findings, symptom or disease.
Conditions Studied
Interventions
- BIOLOGICAL NKX101 - CAR NK cell therapy
Study Locations (8)
Texas
- MD Anderson Cancer Center, University of Texas - Houston
- Methodist Healthcare System of San Antonio - San Antonio
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Mayo Clinic Florida - Jacksonville
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Ohio
- The Cleveland Clinic - Taussig Cancer Institute - Cleveland
Tennessee
- Sarah Cannon at TriStar Bone Marrow Transplant Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2020-09-21 |
| Est. Completion | 2039-07 |
| Phase | Phase 1 |
What the registry record for NCT04623944 still lists
NCT04623944 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 94-participant average among 22 other MDS trials with a reported enrollment target (35% lower).
The record links to 4 conditions, with MDS appearing as the primary indexed condition, and to 1 intervention - of which NKX101 - CAR NK cell therapy is the first listed.
NCT04623944 lists 8 locations in 7 states (Texas, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT04623944 about?
NCT04623944 is a clinical study titled "NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS". This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.
What is the current status of trial NCT04623944?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2020-09-21. Estimated completion is 2039-07.
What conditions does trial NCT04623944 study?
This clinical trial studies the following conditions: MDS, AML, Adult, Refractory Myelodysplastic Syndromes, Relapsed/Refractory AML.
What interventions are being tested in trial NCT04623944?
The interventions under investigation include: NKX101 - CAR NK cell therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT04623944?
This trial is sponsored by Nkarta, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04623944 being conducted?
This trial has 8 study locations across Colorado, Florida, Georgia, Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04623944's enrollment target sits among peer trials
61 7th of 22 higher than 16 of 22 other MDS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other MDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 1
-
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 1
-
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI